{"entity":{"id":"dllevate","kind":"trial","name":"A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)","aka":["DLLEVATE"],"tldr":"A phase 3 trial testing ZL-1310 in non-small-cell lung cancer, now recruiting.","summary":"A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) is a phase 3 interventional study registered as NCT07218146, led by Zai Lab (Shanghai) with Zai Lab (US), and recruiting on the registry. Official title: A Randomised, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator's Choice Therapy in Participants With Relapsed Small Cell Lung Cancer. Planned enrolment is 480 participants (estimated). The study started in 2025-11-30 and primary completion is expected in 2028-06-30. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07218146","url":"https://clinicaltrials.gov/study/NCT07218146"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","extensive-stage-sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["zl-1310"],"companies":["zai-lab"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07218146","phase":"3","setting":"A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator's Choice Therapy in Participants With Relapsed Small Cell Lung Cancer","sponsor":"Zai Lab (Shanghai)","participation":[{"nct":"NCT07218146","source":"https://clinicaltrials.gov/study/NCT07218146","fetchedAt":"2026-10-07T16:55:33.599Z","studySha256":"45dbcfe4a6b05616241f6d2d7fc824626c14fc6c35884d46361b0edaae951305","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-14","leadSponsor":"Zai Lab (Shanghai) Co., Ltd.","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":480,"enrolmentType":"ESTIMATED","siteCount":155,"recruitingSiteCount":155,"countries":["Austria","Belgium","China","Czechia","France","Germany","Greece","Italy","Japan","Netherlands","Poland","Spain","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2025-11-30","startedType":"actual","enrolled":480,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/dllevate/","neighbours":{"cancer":[{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"zl-1310","kind":"drug","name":"ZL-1310","route":"/drugs/zl-1310/"}],"company":[{"id":"zai-lab","kind":"company","name":"Zai Lab","route":"/companies/zai-lab/"}]}}